Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin M Posadas

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2014
miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancerMurali Gururajan, Sajni Josson, Gina Chia-Yi Chu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2020
Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib StudyEdwin M Posadas, Kim N Chi, Ronald de Wit, et al.
European Urology|February 8, 2016
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate CancerScott T Tagawa, Edwin M Posadas, Justine Bruce, et al.
The Oncologist|September 8, 2018
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell CarcinomaToni K Choueiri, M Dror Michaelson, Edwin M Posadas, et al.
BMC Cancer|June 2, 2023
A cisplatin conjugate with tumor cell specificity exhibits antitumor effects in renal cancer modelsStefan Mrdenovic, Yanping Wang, Lijuan Yin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 1, 2022
Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefitBethany N Smith, Rajeev Mishra, Sandrine Billet, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 16, 2025
CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancerManish Thiruvalluvan, Sandrine Billet, Zhenqiu Liu, et al.
Journal of Applied Oral Science : Revista FOB|November 19, 2025
Monocytes and Macrophage-derived mediators influence the behavior of squamous cell carcinoma cell linesGraziela Perri, Raíssa Gabrieli Candido, Luiz Henrique Camargo Soares, et al.
Cancer Cell|March 16, 2017
MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell InteractionsJason Boyang Wu, Lijuan Yin, Changhong Shi, et al.
Cancer Research|February 17, 2017
MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate CancerValentina R Minciacchi, Cristiana Spinelli, Mariana Reis-Sobreiro, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2014
miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancerMurali Gururajan, Sajni Josson, Gina Chia-Yi Chu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2020
Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib StudyEdwin M Posadas, Kim N Chi, Ronald de Wit, et al.
European Urology|February 8, 2016
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate CancerScott T Tagawa, Edwin M Posadas, Justine Bruce, et al.
The Oncologist|September 8, 2018
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell CarcinomaToni K Choueiri, M Dror Michaelson, Edwin M Posadas, et al.
BMC Cancer|June 2, 2023
A cisplatin conjugate with tumor cell specificity exhibits antitumor effects in renal cancer modelsStefan Mrdenovic, Yanping Wang, Lijuan Yin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 1, 2022
Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefitBethany N Smith, Rajeev Mishra, Sandrine Billet, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 16, 2025
CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancerManish Thiruvalluvan, Sandrine Billet, Zhenqiu Liu, et al.
Journal of Applied Oral Science : Revista FOB|November 19, 2025
Monocytes and Macrophage-derived mediators influence the behavior of squamous cell carcinoma cell linesGraziela Perri, Raíssa Gabrieli Candido, Luiz Henrique Camargo Soares, et al.
Cancer Cell|March 16, 2017
MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell InteractionsJason Boyang Wu, Lijuan Yin, Changhong Shi, et al.
Cancer Research|February 17, 2017
MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate CancerValentina R Minciacchi, Cristiana Spinelli, Mariana Reis-Sobreiro, et al.
Pageof 12